Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

43.61USD
3:14pm EST
Change (% chg)

$0.01 (+0.02%)
Prev Close
$43.60
Open
$43.47
Day's High
$43.75
Day's Low
$43.02
Volume
41,052
Avg. Vol
58,003
52-wk High
$54.70
52-wk Low
$40.74

RDY.N

Chart for RDY.N

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.53
Market Cap(Mil.): $7,485.68
Shares Outstanding(Mil.): 170.74
Dividend: 0.30
Yield (%): 0.69

Financials

  RDY.N Industry Sector
P/E (TTM): 46.69 29.84 30.76
EPS (TTM): 0.93 -- --
ROI: 8.03 15.39 14.82
ROE: 9.08 16.58 16.24

BRIEF-Dr. Reddy's Labs says U.S. FDA re-audit of co's plants part of "usual activity"

* Clarifies on news item "FDA to re-audit three Dr.Reddy's labs plants"

Jan 12 2017

BRIEF-Dr.Reddy's Laboratories announces launch of Raloxifene HCI tablets in the U.S.

* Announces the launch of Raloxifene HCI tablets, USP in the U.S. Market Source text: http://bit.ly/2fHr5V4 Further company coverage:

Nov 11 2016

BRIEF-Sucampo Q3 adjusted EPS $0.28

* Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance

Nov 09 2016

BRIEF-Dr.Reddy's Labs exec says co has addressed all FDA requirements on warning letters

* Exec says have addressed all FDA requirements on warning letters

Oct 25 2016

BRIEF-Dr.Reddy's Laboratories Sept-qtr consol profit falls 60 pct

* Co to continue to focus on launching new products in generic business

Oct 25 2016

BRIEF-Dr. Reddy's Labs launches Aripiprazole tablets, USP tablets in U.S. market

* Dr. Reddy's Laboratories announces the launch of Aripiprazole tablets, USP tablets in the U.S. market Source text for Eikon: Further company coverage: (Bengaluru newsroom)

Oct 13 2016

BRIEF-Dr.Reddy's launches Lamotrigine Orally Disintegrating tablets in U.S

* Announces the launch of Lamotrigine Orally Disintegrating tablets in the U.S. market Source text: http://bit.ly/2dFkVt2 Further company coverage:

Oct 10 2016

BRIEF-Dr.Reddy's Labs announces entry into Columbia

* Announces entry into Columbia Source text: http://bit.ly/2dzOUiD Further company coverage: (Bengaluru newsroom)

Oct 07 2016

BRIEF-DR. Reddy's laboratories says launch of Bupropion HCL extended-release tablets, USP (sr) in U.S. market

* Launch of bupropion hcl extended-release tablets, usp (sr) in u.s. Market Source text for Eikon: Further company coverage:

Sep 02 2016

Earnings vs. Estimates